ArticleBMC oral health2026
CXCL10 as a migration-associated biomarker in oral squamous cell carcinoma.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOral squamous cell carcinoma (OSCC) is marked by aggressive local invasion and early metastasis, yet molecular biomarkers linked to tumor cell motility remain insufficiently defined. CXCL10, an interferon-inducible chemokine, exhibits context-dependent roles across cancers, but its functional relevance to OSCC migration has not been fully elucidated.
methodsThree GEO transcriptomic datasets (GSE13601, GSE160042, GSE227919) were analyzed to identify differentially expressed genes (DEGs). Functional enrichment, STRING–Cytoscape protein–protein interaction analysis, and CytoHubba/MCODE were used to prioritize hub genes. A random-effects meta-analysis quantified the pooled expression differences of key candidates. CXCL10 expression was validated using UALCAN, CPTAC, and an independent OSCC tissue microarray. The functional role of CXCL10 was examined via siRNA-mediated knockdown and recombinant CXCL10 treatment in HSC3 and SCC4 cell lines using wound-healing and Transwell migration assays.
resultsA total of 263 overlapping DEGs were identified across the three cohorts, enriched in pathways related to extracellular matrix organization, focal adhesion, immune regulation, and antiviral responses. Network analyses identified five hub genes, among which CXCL10 demonstrated the highest pooled overexpression in OSCC (log₂FC = 4.27; 95% CI 2.02–6.52). UALCAN and CPTAC analyses confirmed elevated CXCL10 transcript and protein levels in tumor tissues, which were further validated by tissue-array immunohistochemistry. Functionally, CXCL10 knockdown significantly reduced OSCC cell migration, whereas recombinant CXCL10 dose-dependently enhanced motility.
conclusionsCXCL10 is markedly overexpressed in OSCC and contributes to tumor cell motility in vitro. These findings support CXCL10 as a migration-associated candidate biomarker with potential clinical relevance, warranting further validation in OSCC cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.